"As we deliver our first $3 billion quarter in Q2 2026, it is clear that our Arista 2.0 platform strategy is compelling," ...
The math behind Social Security's looming funding gap is becoming painfully real for retirees. Congress has known for years ...
Bill Ackman, the founder and CEO of Pershing Square Capital Management, has an impeccable record, as his firm has ...
My view is that Johnson & Johnson is a much better pick between these two companies right now. The pharmaceutical leader ...
The memory giant is retiring roughly one share in every 30 -- and it says its shareholder-return target is moving from a ...
Oracle's surging backlog initially lifted its stock, but the scope of its relationship with OpenAI cast doubt on the security ...
Recent results and legalization progress aren't the game changers you'd think they'd be for this cannabis stock.
Axsome Therapeutics ( AXSM -0.13%), a biotech company, has performed fairly well this year. The company's shares are up 16% ...
The nuclear start-up just proved it can build a reactor in 11 months. Selling electricity from one runs on a different ...
ExxonMobil's status as an oil dividend stock royalty is further supported by cold, hard cash. Under its 2030 plan, the oil ...
Nvidia looks like a screaming bargain right now, and investors should act fast.
History says the market will eventually collapse, but this time does look different.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results